Commonly used antibiotic brings more complications, death in the sickest patients

Providers are required to quickly determine which antibiotics to use when patients are facing a life threatening infection. But a study finds that these decisions may have unintended consequences

12:24 PM

Author | Kelly Malcom

blue gloves in hospital hanging IV bag
Getty Images

In emergency rooms and intensive care units across the country, clinicians make split-second decisions about which antibiotics to give a patient when a life-threatening infection is suspected. 

A Michigan Medicine study reveals that these decisions may have unintended consequences for patient outcomes.

Beginning in 2015, a 15-month national shortage of a commonly prescribed antibiotic, piperacillin/tazobactam, known by the brand name Zosyn, provided a unique opportunity to compare rates of death in hospitalized patients with sepsis who were administered two different types of antibiotics—one that spares the gut microbiome and one that profoundly alters it. 

Piperacillin/tazobactam is a broad-spectrum antibiotic that is commonly administered for sepsis, a life-threatening complication from infection. 

In its absence, clinicians commonly instead use another antibiotic, cefepime, which has similar activity against common sepsis pathogens but, unlike piperacillin/tazobactam, has minimal effects on anaerobic gut bacteria.

“We saw this Zosyn shortage as a one-of-a-kind opportunity to ask whether this antibiotic, which we know depletes the gut of anaerobic bacteria, makes a difference in terms of patient outcomes,” said Robert Dickson, M.D. of the Department of Medicine’s Division of Pulmonary & Critical Care Medicine and deputy director of the Weil Institute for Critical Care Research & Innovation.

In health, the gut microbiome is largely populated by anaerobic bacteria that rarely cause disease. 

Prior work by the study team has revealed that even a single dose of piperacillin/tazobactam kills most of these anaerobic gut bacteria, which play important roles in the body’s metabolism, immunity, and prevention of infections.

Dickson, Rishi Chanderraj, M.D., of the Division of Infectious Disease, Michael Sjoding, M.D., of the Division of Pulmonary & Critical Care Medicine and their multidisciplinary team at U-M and the VA Ann Arbor used patient record data to look at outcomes in 7,569 patients. 

The team compared 4,523 patients who were treated were piperacillin/tazobactam with 3,046 patients who received cefepime. 

They found marked differences: treatment with piperacillin-tazobactam was associated with a 5% increase in 90-day mortality, more days on a ventilator, and more time with organ failure. 

When we looked at two-week outcomes in our study, we didn’t find differences either. But the differences at three months were dramatic.” Rishi Chanderraj, M.D.

“These are powerful antibiotics that are administered to patients every day in every hospital nationwide,” said Chanderraj. 

“Clinicians use them because they are trying to treat every possible pathogen that might be causing their patients’ illness. But our results suggest that their effects on the microbiome might also have important effects on patient outcomes.”

The study builds on previous work by the study team that suggested critically ill patients may do worse when given antibiotics that deplete the gut of anaerobes. 

They have also seen similar effects when studying animal models.

“Our prior work suggested that there might be harm with piperacillin/tazobactam, but it was an observational study that had some limitations,” said Sjoding, the study’s senior author. 

“That’s why the drug shortage was such an amazing opportunity. It created an almost perfect natural experiment that let us test the difference between these two drugs on patient outcomes in a very rigorous manner.”

A recent clinical trial pitted these two antibiotics against each other and compared side effects and mortality after two weeks. That trial did not find any differences in the short term—a finding that the U-M team also observed in their analysis.

“When we looked at two-week outcomes in our study, we didn’t find differences either,” said Chanderraj. “But the differences at three months were dramatic.”

Overall, the new findings suggest that treatment with piperacillin/tazobactam instead of cefepime may contribute to one additional death per every 20 septic patients treated. 

“A 5% mortality difference has enormous implications because sepsis is so common,” said Dickson. “Every day, thousands of clinicians are deciding which of these drugs to use in septic patients.”

Physicians should give more thought about whether anti-anerobic antibiotics are warranted before prescribing them, added Chanderraj. “We need to think about antibiotics like chemotherapy. In the right context, treatment can be lifesaving, but in the wrong context, it can be quite harmful.”

Additional authors: Andrew J. Admon MD, MSc MPH, Ying He PhD, Mark Nuppnau MSc, Owen R. Albin MD, and Hallie C. Prescott MD MSc.

Citation: “Comparing mortality of sepsis patients administered piperacillin-tazobactam or cefepime using instrumental variable analysis,” JAMA Internal Medicine, doi:10.1001/jamainternmed.2024.0581

Sign up for Health Lab newsletters today. Get medical tips from top experts and learn about new scientific discoveries every week by subscribing to Health Lab’s two newsletters, Health & Wellness and Research & Innovation.

Sign up for the Health Lab Podcast: Add us on SpotifyApple Podcasts or wherever you get you listen to your favorite shows.


More Articles About: All Research Topics infectious disease Pharmacy
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories pills floating blue pink dark background physician in middle looking at chart white coat scrubs
Health Lab
Better medical record-keeping needed to fight antibiotic overuse, studies suggest
Efforts to reduce overuse of antibiotics may be hampered by incomplete medical records that don’t show the full reasons for prescriptions.
surgery gloves passing tool blue and yellow
Health Lab
A universal heparin reversal drug is shown effective in mice
The newest version of the heparin reversal drug, described in a recent issue of Advanced Healthcare Materials, adjusted the number of protons bound to it, making the molecule less positive so it would preferentially bind to the highly negative heparin, resulting in a much safer drug.
wheelchair walker image
Health Lab
Spread of drug resistant bacteria linked to patient hand contamination and antibiotic use within nursing homes
A Michigan Medicine research team seeks to identify characteristics of patients within nursing homes, as well as the nursing home environment itself, that are associated with contamination by vancomycin-resistant enterococci.
dna strand colorful
Health Lab
A promising new target for antibiotics
A promising target for new and improved antibiotics are riboswitches, small stretches of RNA that regulate a process necessary for the production of proteins by the bacterial cell.
colorful pills falling in a line
Health Lab
For COVID-19, do supplements help?
An expert cautions about becoming too enamored with pills.
Sewing Machine Cell Fabric Tangled
Health Lab
Research points to potential new treatment for aggressive prostate cancer subtype
In two separate papers, U-M researchers describe how a gene alteration drives prostate cancer and a potential degrader that stops it